drug

Sibutramine

MeSH C058254
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Eli Lilly and Company
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044187Phase 4Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Eli Lilly and Company
company
trial
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
PHASE4
trial
indication
Schizophrenia
indication
Bipolar Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication